T he relationship between the occurrence of intraventricular hemorrhage (IVH) in patients with intracerebral hemorrhage (ICH) and the likelihood of death or poor neurologic outcome has been consistently demonstrated in a growing number of pro spective studies and clinical trials, including the International Surgical Trial in Intracerebral Hemorrhage study and the recombinant activated factor VII for acute intracerebral hemorrhage (NovoSeven) trials (1) (2) (3) (4) (5) (6) (7) (8) (9) .
Massive IVH leads to acute hydrocephalus, which compresses the rostral brainstem and thalamus causing injury to the reticular activating system and may decrease cerebral perfusion pressure contributing to ischemic injury (10, 11) . Elevated intracranial pressure Objectives: Elevated intracranial pressure is one of the proposed mechanisms leading to poor outcomes in patients with intraventricular hemorrhage. We sought to characterize the occurrence and significance of intracranial hypertension in severe intraventricular hemorrhage requiring extraventricular drainage.
Design: Prospective analysis from two randomized, multicenter, clinical trials.
Setting: Intensive care units of 23 academic hospitals.
Patients: One hundred patients with obstructive intraventricular hemorrhage and intracerebral hemorrhage volume <30 mL requiring emergency extraventricular drainage from two randomized multicenter studies comparing intraventricular recombinant tissue plasminogen activator (n = 78) to placebo (n = 22).
Interventions: Intracranial pressure was recorded every 4 hrs in all patients and before and after a 1-hr extraventricular drainage closure period after injection. Intracranial pressure readings were analyzed at predefined thresholds and compared between treatment groups, before and after injection of study agent, and before and after opening of third and fourth ventricles on computed tomography. Impact on 30-day outcomes was assessed.
Measurements and Main Results: Initial intracranial pressure ranged from 22 to 60 mm Hg (median; interquartile range, 11;10). Of 2576 intracranial pressure readings, 91.5% (2359) were 20 mm Hg, 1.6% were >30, 0.5% were >40, and 0.2% were >50 mm Hg. In a multivariate analysis, threshold events >20 mm Hg and >30 mm Hg were more frequent in placebo vs. recombinant tissue plasminogen activator-treated groups (p = .03 and p = .08, respectively). Intracranial pressure elevation >20 mm Hg occurred during a required 1-hr extraventricular drainage closure interval in 207 of 868 (23.8%) injections of study agent, although early reopening of the extraventricular drainage only occurred in 7.9%. After radiographic opening of the lower ventricular system, intracranial pressure events >20 mm Hg remained significantly associated with initial intraventricular hemorrhage volume (p = .002) and extraventricular drainage placement ipsilateral to the largest intraventricular hemorrhage volume (p = .001), but not with thrombolytic treatment (p = .05) or intracerebral hemorrhage volume (p = .14). Ventriculoperitoneal shunts were required in 13.6% of placebo and 6.4% of recombinant tissue plasminogen activator-treated patients (p = .37). Percentage of intracranial pressure readings per patient >30 mm Hg and initial intracerebral hemorrhage and intraventricular hemorrhage volumes were independent predictors of 30-day mortality after adjustment for other outcome predictors (p = .003, p = .03, and p < .001, respectively). Independent predictors of poor modified rankin scale score at 30 days were percent of intracranial pressure events >30 mm Hg per patient (p = .01; but not >20 mm Hg), both intracerebral hemorrhage and intraventricular hemorrhage volume, and pulse pressure.
Conclusions: Intracranial pressure is not frequently elevated during monitoring and drainage with an extraventricular drainage in patients with severe intraventricular hemorrhage, although intracranial pressure >30 mm Hg predicts higher short-term mortality. Thrombolytic therapy may reduce the frequency of high intracranial pressure events. Intracranial pressure elevation appears to be significantly correlated with extraventricular drainage placement in the ventricle with greatest clot volume. ( (12) . To better understand the occurrence of elevated ICP in IVH and its role in neurologic deterioration, we performed a more detailed analysis of ICP using data from the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR IVH) trial, a large, placebo-controlled, multisite trial to evaluate low-dose intraventricular recombinant tissue plasminogen activator (rt-PA) for the treatment of ICH with IVH. This represents the largest cohort to date of prospectively collected severe IVH patients managed with aggressive neurointensive care. The goal of this study was to investigate frequency of and factors associated with ICP elevation during EVD use, tolerance of EVD closure for intraventricular study agent administration, and impact of ICP on early mortality and neurologic outcomes.
MATERIALS AND METHODS

Patients.
One hundred adult patients with obstructive hydrocephalus secondary to IVH and ICH volume <30 mL (by ABC/2 method) (13) requiring EVD (per the treating physician) from two multicenter trials (CLEAR IVH Trials) were prospectively studied. The CLEAR IVH Trial study procedures have been published previously (14, 15) . All eligible patients with an EVD inserted within the initial 24 hrs of the diagnostic computed tomography (CT) scan were approached for randomization. Patients were enrolled within 48 hrs after the diagnostic head CT. Exclusion criteria included posterior fossa hematoma, intraparenchymal hemorrhage volume >30 mL, suspected intracerebral aneurysm or arteriovenous malformation (excluded by appropriate diagnostic studies), any severe complicating illness, active internal bleeding, current use of heparin, coagulopathy with prothrombin time or partial thromboplastin time outside of normal range, platelet count <75 IU/ mm 3 , pregnancy, and age younger than 18 yrs. Randomization and Masking. The CLEAR IVH trials comprised a safety Trial (n = 48) and a dose-finding trial (n = 52). In the safety trial, patients were randomly assigned (1:1) to intraventricular administration of placebo (placebo; n = 22) or rt-PA (n = 26) at a dose of 3.0 mg every 12 hrs. In the dose-finding study, patients were randomized 1:1 (n = 16) either to receive intraventricular rt-PA at doses 0.3 or 1.0 mg every 12 hrs (CLEAR A) or to receive 1.0 mg every 12 hrs or every 8 hrs (n = 36; CLEAR B) (Fig. 1) . Patients in this study include all enrolled patients in the CLEAR IVH trials.
Procedures. Treatments for ICP management such as hyperventilation and osmotic therapy were administered per the treating physician for sustained (>5 mins) ICP >20 mm Hg. EVDs were placed into the frontal horn of the lateral ventricle and tunneled under the scalp by neurosurgical staff. In the absence of accepted practice guidelines regarding catheter location, the choice of catheter placement ipsilateral or contralateral to dominant lateral ventricular IVH was left to each site's neurosurgical team. Please refer to the supplemental Materials and Methods for other procedural details (see Supplemental Digital Content 1, http://links.lww.com/CCM/A397).
ICP and cerebral perfusion pressure (CPP) management were based on the Brain Trauma Foundation Guidelines and were performed continuously per each intensive care unit's protocol (16, 17) . ICP management was protocolized by the study only for the hour after dosing when the EVD was closed. The EVD was to be reopened within the initial hour only if needed to control medically intractable ICP elevation (ICP >20 mm Hg refractory to hyperventilation and mannitol administration).
The daily cerebrospinal fluid (CSF) volume drained was recorded. The decision for ventriculoperitoneal (VP) shunt placement was at the discretion of the treating neurosurgeon.
ICP and CPP Determination. ICP was recorded at the end of every 4-hr interval in all patients and every 1 hr in 36 patients. ICP was also recorded before and after a 1-hr EVD closure period after injection. For each recorded ICP measurement, the EVD was closed for 10 mins and the ICP was recorded at the end of this time period.
CPP was recorded with each ICP measurement. Low CPP events were defined at thresholds of CPP <60 or CPP <70 mm Hg. CPP <60 mm Hg and ICP >20 mm Hg were considered threshold levels for treatment based on Brain Trauma Foundation Guidelines (16, 17) .
IvH and ICH volume Determination
Daily head CT scans were obtained during study agent administration per protocol, and additional CT studies were performed for acute neurologic deterioration per the treating physician. The first CT scan performed at least 6 hrs after EVD placement that demonstrated stable IVH and ICH volume and either no or stable catheter tract hemorrhage was designated the "stability CT." The volumes of intraventricular and intraparenchymal hematomas were measured independently by a blinded investigator using standard computerized volumetric analysis (Alice 5.1; Perceptive Informatics, Boston MA). This represents a more rigorous method to recalculate volumes for analysis compared to the ABC/2 method used for ICH volume determination for patient enrollment. Clearance of blood from the third and fourth ventricles (ability to visualize a clear pathway of hypodense CSF through the lower ventricular system) was similarly assessed. This protocol was approved by the Internal Review Boards of all enrolling institutions.
Statistical Analysis
Demographic variables, stability IVH and ICH volumes, total duration of ICP monitoring, and differences in median ICP before and after injection of study agent as well as before and after blood clearance from the third and fourth ventricles were compared between rt-PA and placebo-treated patients. Frequency of high ICP threshold events (ICP >20, 30, 40, or 50 mm Hg) by treatment group and by frequency of ICP data recordings (every 1 hr vs. every 4 hrs) was also compared. Wilcoxon rank-sum test was used to compare variables with non-normal distributions. Student t test was used for continuous variables with normal distributions and chi-square or Fisher exact test was used for analysis of categorical data as appropriate. Univariate and multivariate analyses of factors associated with ICP and CPP levels and thresholds were performed with linear and logistic regression models, with clustering by patient to adjust for multiple readings per patient. The following outcome variables were considered in the analysis: the number of ICP readings per patient >20 and >30 mm Hg over the entire monitoring period, during EVD closure for study agent administration, and after the third and fourth ventricles had opened on CT; early opening of the EVD before the 1-hr recommended closure time; VP shunt placement; average daily CSF volume drained from the EVD; the proportion of CPP readings <60 and <70 mm Hg; and 30-day outcomes (mortality and modified Rankin Scale score.
Independent predictors considered for ICP outcomes were treatment group, stability ICH and IVH volumes, catheter location, presenting Glasgow Coma Scale (GCS) score, ICP immediately before EVD closure, ICP >30 mm Hg during EVD closure, and proportion of ICP events >20 mm Hg not associated with EVD closure. Independent predictors considered for VP shunt placement were proportion of ICP readings >20 and >30 mm Hg, IVC duration, time from EVD placement to opening of third and fourth ventricles, IVH volume, presenting GCS score, and treatment. Independent predictors considered for average daily CSF volume drained from the EVD were treatment group, proportion ICP readings >30 mm Hg, IVC duration, IVH volume, and ICH volume. Independent predictors considered for the proportion of CPP readings <60 and <70 mm Hg were proportion of ICP readings >20 mm Hg, ICH volume, and IVH volume.
For outcome evaluation, the modified Rankin Scale score at 30 days was dichotomized as good outcome (modified Rankin Scale score 0-4) and poor outcome (modified Rankin Scale score 5-6). Covariates considered in the final outcome models were number of ICP events per patient with readings >30 mm Hg and variables known to be associated with outcome after ICH if they were significantly associated with 30-day mortality or poor modified Rankin Scale score, respectively, on univariate analysis (p < .1). These included presentation GCS score and pulse pressure, age, baseline ICH and IVH volumes, and treatment with any dose of intraventricular rt-PA. Statistical significance was assigned for p  .05. Data are presented as median ± interquartile range or mean ± SD, unless otherwise indicated.
RESULTS
Baseline Clinical Characteristics
One hundred patients were enrolled with age range 28 to 75 yrs (mean, 55 ± 10 yrs) ( Table 1 ). Treatment groups did not differ with respect to age, race, stroke risk factors, or baseline clinical and radiologic parameters. There were significantly more males in the rt-PA-treated group (68% male vs. 32% male in placebo group; p = .002).
All patients had EVDs inserted within 24 hrs of the diagnostic CT scan (median, 0.2 days; minimum-maximum, 0.01-1.1 days). With reference to the majority of lateral ventricular blood, the initial EVD was inserted in the ipsilateral lateral ventricle in 22 patients and in the contralateral lateral ventricle in 71. Patients with ipsilateral or contralateral EVD placement did not differ with regard to treatment group, stability ICH and IVH volume, average daily CSF volume, and all demographic and presenting characteristics. Seven patients had two simultaneous catheters (one on each side). These patients had significantly larger IVH volume (median, 104.8 vs. 34.7 mL; p = .004) and nonsignificantly lower presentation GCS score (median, 5 vs. 8; p = .36) compared to patients with single EVDs only. More than one EVD was placed in 47 patients (27 had 2 EVDs; 11 had 3 EVDs; 7 had 4 EVDs; and 2 had 5 EVDs). The EVD became obstructed more often (requiring replacement) in placebo compared with rt-PA-treated patients (40.9% vs. 11.8%; p = .002). VP shunts were required in 14% of placebotreated patients and 6% of rt-PA-treated patients (p = .27).
Stability IVH and ICH volumes were not different between treatment groups. Stability IVH volume was positively correlated with time to clearance of blood from the third, but not the fourth, ventricle (Spearman  = 0.22, p = .03,  = 0.09, and p = .42, respectively). 17 (22) 3 (14) 20 (20) .40 Migraine (%)
1 (1) 1 (5) 2 (2) .33 History of seizure (%) 7 (9) 0 (0) 7 (7) .14 Hx of alcohol abuse (%)
13 (17) 6 (27) 19 (19) .26 Hx of tobacco use (%) 20 (26) 2 (9) 22 (22) .10 Hx of cocaine abuse (%)
12 (15) 2 (9) 14 (14) . (28) 130 (28) 135 (28) .37 Pulse pressure a 86 (26) 88 (21) 86 (25) .71 Opening intracranial pressure b 11 (9) 13 (11) 11 (10) .83 Cerebral perfusion pressure b 84 (18) 87 (24) 85 (24 
ICP Readings During EvD Monitoring Period
The median duration of EVD (and ICP monitoring) was 8.6 days (interquartile range, 7.3) and was shorter in the rt-PAtreated group (8.4), but it was not statistically different from placebo (11.0) ( Table 2) .
Of 2576 ICP readings (taken every 4 hrs), 91.5% (2359) were 20 mm Hg, 8.5% were >20 (in n = 49 patients), 1.6% were >30 (n = 15), 0.5% were >40 (n = 5), and 0.2% were >50 mm Hg (n = 4). Groups are not mutually exclusive. In a multivariate analysis, the proportion of threshold ICP events >20 mm Hg and >30 mm Hg per patient were significantly more frequent in the placebo-treated group (ICP >20 mm Hg only; p = .03 and p = .08, respectively) (Fig. 2) , in patients with initial EVD placement ipsilateral to the side of greatest IVH clot volume (vs. contralateral; p = .01 and p < .001, respectively) (Fig. 3) , those with larger stability IVH volume (p < .001 and p < .001, respectively) but not with stability ICH volume (p = .37 and p = .26, respectively), and in patients with a higher presentation GCS score (p = .007 and p = .01, respectively).
Fifty-one patients, 43 (55%) rt-PAtreated and eight (36%) placebo-treated, had no ICP readings >20 mm Hg for the duration of their EVD. Table 3 shows the characteristics of patients with and without ICP readings >20 mm Hg. Other demographic and presenting characteristics (not shown) were not different between these two groups with the exception that presenting mean arterial pressure was higher in the group with any ICP reading >20 mm Hg (127 [32] vs. 113 [29] with no ICP reading >20 mm Hg; p = .03). Clot location was not associated with any occurrence of elevated ICP. All seven patients treated with simultaneous initial placement of dual EVDs had at least one ICP reading >20 mm Hg, although only one of these had ICP >30 mm Hg. Comparison of 2676 every 1 hr compared with 894 every 4 hrs for ICP readings in a subset of 36 patients showed no significant difference in proportion of readings above ICP threshold events (p = .97).
ICP Monitoring During EvD Closure for Study Agent Administration
The median change in ICP per patient during 1-hr EVD closure period after injection of study agent was an increase of 4 mm Hg (interquartile range, 8) and was not different between treatment groups (p = .54). Of 868 intraventricular injections of study agent, ICP elevations >20 and >30 mm Hg occurred during EVD closure in 23.8% (n = 59 patients; 207 injections) and 6.2% (n = 26; 54 injections) of injections, respectively. ICP elevation >30 mm Hg by the end of the closure period was independently associated with higher pre-EVD closure ICP (p < .001) and with higher initial GRAEB score (p = .04), but not with treatment group (p = .59), stability IVH volume (p = .15), stability ICH volume (p = .57), or side of EVD placement relative to greatest IVH clot volume (p = .13). The number of ICP elevations >20 mm Hg per patient during EVD closure for the first ten doses of study agent was significantly associated with having any ICP readings >20 mm Hg during non-EVD closure times (p = .003). Early opening of the EVD before 90% of the recommended 1-hr closure time had elapsed occurred in 69 (7.9%) injections (n = 35 patients) and was independently associated with ICP >30 mm Hg during closure (p = .003, adjusted for number of injections/patient) and with rt-PA treatment (p = .004), but not with the immediate preinjection ICP (p = .61) or with stability IVH volume (p = .12) or ICH volume (p = .40).
ICP Monitoring Before and After Clearance of Lower ventricular System
Clearance of blood from both the third and fourth ventricles, as visualized on CT scan, occurred at a median of 2.5 days (2.0) in the rt-PA group compared to 6.4 days (4.6) in the placebo group (p < .001). The proportion of ICP readings >20 mm Hg after clearance was significantly greater in patients with ipsilateral placement of EVD (p = .001), larger stability IVH volume (p = .002), longer time to opening of third ventricle (p = .001), and was marginally greater in rt-PAtreated patients (p = .05) but was not associated with stability ICH volume (p = .14). Median ICP was unchanged before compared with after clearance (p = .09). Three surviving patients in each group (3.8% rt-PA; 13.6% placebo) did not have radiographic clearance of both the third and fourth ventricles.
CSF Drainage and vP Shunt Insertion
Median daily CSF drainage was 109 mL (153) in the placebo group compared with 53 mL (138) in the rt-PA-treated group. Average daily CSF volume drained per patient was significantly higher with longer EVD duration (p < .001) and larger stability ICH volume (p = .02), but was not associated with stability IVH volume (p = .41), treatment (p = .54), or number of high ICP events >20 mm Hg (p = .87) or >30 mm Hg (p = .47). We did not adjust the model for daily IVH volume because not all patients had daily CT scans beyond the first 2 days of admission.
In the multivariate analysis of factors associated with VP shunt insertion, there was a significant association with proportion of ICP readings >20 mm Hg (p = .03), but it was only marginal for ICP >30 mm Hg (p = .05). VP shunt insertion was also significantly associated with placebo treatment (p = .04), lower presentation GCS score (p = .03), longer time to opening of the third ventricle (p = .01), longer EVD duration (p = .004), but not with stability IVH volume (p = .40) or GRAEB score (p = .24). The number of VP shunts placed was not significantly different between treatment groups (6.4% rt-PA vs. 13.6% placebo; p = .37).
CPP Monitoring
Baseline CPP ranged from 52 to 147 mm Hg (median, 83.5; interquartile range, 21.3). Over the entire ICP monitoring period, low CPP events <60 mm Hg but not <70 mm Hg per patient were less frequent in rt-PA compared with placebo-treated patients (p = .02 and p = .25, respectively). CPP events <60 mm Hg were associated with elevated ICP (>20 mm Hg) in seven of 25 (28%) readings (p = .04). CPP events <70 mm Hg were associated with elevated ICP in 25 of 102 (24.5%) readings (p = .01).
30-Day Neurologic Outcomes
Median 30-day modified Rankin Scale score was 5 in both treatment groups (p = .23). Mortality was 19 (19.1%) at 30 days. In the multivariate analysis (adjusting for known predictors of ICH outcome), mortality was significantly associated with the percentage of high ICP events per patient >30 mm Hg (p = .003) and with a trend for percentage of ICP readings >20 mm Hg (p = .08). Mortality was also associated with both IVH and ICH stability volume (Table 4) . Poor modified Rankin Scale score at 30 days was independently associated with percentage of ICP events >30 mm Hg per patient (p = .01), but not >20 mm Hg, and with both ICH and IVH volume and pulse pressure. The rt-PA treatment was not associated with 30-day outcomes.
DISCUSSION
During monitoring, significant ICP elevation occurs in 8.5% of readings after initiation of external CSF drainage for spontaneous IVH with associated hydrocephalus. The corollary is that CSF drainage effectively controls ICP >90% of the time. However, ICP elevation >30 mm Hg, when it occurs, is an independent predictor of short-term mortality, suggesting that EVDs play therapeutic and diagnostic roles in this disease.
This study raises several important issues. First, although ICP elevation was not a frequent event in most patients, the duration of high ICP (especially ICP >30 mm Hg) appears to be important. The use of EVDs should not be considered only for ICP relief, but it is equally important for CSF drainage or clearance of blood to prevent occurrence of ICP elevation. This is supported by the finding that ICP is dependent on ventricular clot volume.
Impact of Intraventricular Thrombolysis on ICP
The hypothesis of the CLEAR IVH studies on which these data are based is that intraventricular clot volume reduction assisted by intraventricular rt-PA will improve long-term neurologic outcomes. The finding that the proportion of high ICP events (>20 mm Hg) was significantly less frequent in the rt-PAtreated group (and borderline significant for >30 mm Hg vs. placebo-treated group) suggests that more effective clot removal lowers the risk of ICP elevation. There was also a nonsignificantly higher percentage of rt-PA-treated patients who had no ICP elevation >20 mm Hg (vs. any ICP elevation). We previously reported a small study of ICP in urokinase compared with placebo-treated patients with IVH in which EVDs were equally effective in controlling ICP in both treatment groups during the first 5 days of monitoring (12) . The current larger study appears consistent with the explanation that thrombolysis improves ICP control. Compared with placebo, rt-PA-treated patients in the current study had less common EVD obstruction requiring replacement, shorter duration of EVD, faster clearance of the lower ventricular system, less frequent VP shunt placement, and fewer low CPP readings. All of these treatment effects may be associated with decreased occurrence of intracranial hypertension.
Thrombolytic therapy did not have an impact on ICP control after radiographic clearance of the third and fourth ventricles while ICP was monitored, although tPA treatment had been stopped by this time. High ICP after apparent establishment of clearance of the lower CSF pathways may occur because of nonobstructive (communicating) hydrocephalus, lack of clearance of blood from lateral ventricles (obstruction of the Foramina of Munro), and challenging the need for EVD by raising the "pop-off" for CSF drainage. The definition of ventricle clearance used was dependent on visualization of hyperdense blood products in the third and fourth ventricles, which may become less reliable with timerelated changes in the appearance of blood on CT.
EVD closure-related ICP elevation occurred after nearly one-quarter of injections, indicating that many patients are highly dependent on CSF drainage to control ICP. However, these events were apparently readily controlled with medical management (or tolerated by the treating physician) such that only a small percentage of injections (7.9%) required early reopening of the EVD. Patients who experienced elevated ICP during EVD closure for study agent administration were also more likely to have high ICP events during CSF drainage. This group may benefit from alternative strategies for delivery of intraventricular thrombolysis. It is conventional to perform equivolumetric exchange of CSF for thrombolytic agent and to close the EVD for some period of time after drug administration to ensure adequate pharmacologic activity. In patients who are not expected to tolerate EVD closure (because of preexisting ICP elevation), techniques such as preemptive ICP management with sedatives to decrease cerebral metabolism (propofol or barbiturates) and use of dual catheters to facilitate CSF removal may provide superior ICP control to that achieved in this study.
Compartmentalization of ICP
The finding that initial EVD placement ipsilateral to the side of greatest IVH clot burden was significantly associated with high ICP (>20 and >30 mm Hg) compared to patients with contralateral EVD placement suggests that ICP may be lateralized in this disease. There are several possible explanations. There may be an ICP gradient within the ventricular system with ICP highest on the side of the greatest clot volume; patients who had ipsilateral drains may have been sicker, had local mass effect or a trapped lateral ventricle at the time of EVD placement; or EVDs placed in the more open ventricle allowed better ICP control because of increased CSF drainage. The concept of ICP compartmentalization has been described in stroke. In patients with bilateral epidural sensors, ICP is higher ipsilateral to the stroke, with a difference up to 15 mm Hg (18) . Compartmentalization of ICP within the ventricle has not been described but has clinical implications because EVDs are often placed contralaterally when IVH produces casting of the most involved ventricle. If ICP is lateralized, then monitoring ICP from the less involved ventricle may fail to demonstrate treatable ICP elevation that occurs on the side of greater clot. Our study results cannot support specific recommendations regarding the most appropriate side of EVD placement because EVD location was chosen at the discretion of the inserting proceduralist and we did not record simultaneous ICP readings in the few patients with dual EVDs.
Mortality and Neurologic Outcome
It is often assumed that a major contributing factor to poor outcomes in patients with ICH and IVH is hydrocephalus and accompanying elevated ICP, which injures the reticular activating system and compromises cerebral perfusion. This study found that the percentage of high ICP (>30 mm Hg) recordings per patient (not in association with EVD clamping for study agent administration) was an independent predictor of 30-day mortality after adjusting for ICH and IVH volumes, age, presentation GCS score, and pulse pressure. This is consistent with the traumatic brain injury literature on the significance of ICP elevation (20 mm Hg) in the first 48 hrs after head injury as a poor prognostic indicator, especially if ICP is refractory to treatment (19, 20) . We also found a significant association between baseline ICH and especially IVH volumes and 30-day outcomes in this cohort. These findings support previously established associations between larger IVH volume and greater degree of ventricular dilation on early CT scans with worse outcomes (21) (22) (23) . Because ICP was aggressively managed in this protocol, it is not clear whether outcomes could be improved with more intensive treatment of ICP elevations or if the observed intracranial hypertension is a treatment-refractory marker of disease severity.
Our finding that admission pulse pressure was an independent predictor of poor outcome (but not mortality at 30 days) is consistent with the literature (24, 25) . This finding was independent of proportion of ICP readings >30 mm Hg. Other possible mechanisms for this association are that patients with higher blood pressure had increased perihematomal edema or hematoma expansion, which was not captured as higher ICP, or had ischemic strokes, which we did not evaluate. Early recurrence of acute ischemic stroke has been associated with both high systolic and diastolic blood pressures (24, 26) . It may also be that initial higher blood pressures were a physiologic response to very high ICP, which was not recorded before EVD placement and resulted in worse outcomes.
Previous observations in patients with ICH and IVH suggest that EVD placement alone is not sufficient to result in improved outcomes, and that morbidity associated with hydrocephalus may precede EVD placement. Adams and Diringer (27) reported EVD placement was associated with "adequate" control of ICP in 20 of 22 patients with supratentorial ICH and hydrocephalus, although neither ventricular size nor level of consciousness improved in the short-term. Diringer et al (23) reported that hydrocephalus was associated with higher intubation rates and mortality in 81 patients with supratentorial ICH, although outcomes in patients treated with EVD were not different from those not treated with EVDs. Coplin et al (28) reported that ICP at insertion of EVD does not appear to have any particular prognostic significance either as an indicator of future high ICP events or as a prognostic indicator of outcome. Although our results do not refute any of these previous findings, this is the first study to show with serial ICP recordings that high ICP (>30 mm Hg) is an independent predictor of short-term survival; therefore, aggressive ICP management may be a sufficient rationale for EVD placement independent of the decision to use thrombolytics.
Study Limitations
The sample size, duration of monitoring and frequency or intensity of monitoring could have limited our ability to observe ICP events and define relationships. That being said, the frequency of high ICP events is plausible and consistent with the frequency of ICP elevation in the previous study using urokinase thrombolysis (12) . Although ICP was aggressively managed in this study, we cannot exclude the possibility of missed events; for example, it is possible that ICP was not managed at standard thresholds in patients who were expected to have poor outcomes. Additionally, by only considering 30-day outcomes, we were not able to determine whether ICP elevation impacts long-term neurologic function. As in our previous study, generalizability is limited to patients with small ICH (<30 mL) and large IVH requiring EVDs. This may also explain why ICH volume and clot location were not associated with ICP. There were relatively few lobar hemorrhages (n = 8), which are often larger and may contribute more to ICP elevation. Variability in clot localization and size were constrained by study inclusion criteria, thus limiting the influence of these otherwise important factors on outcome and mortality. Our study showed that median ICP and proportion of high ICP events above threshold were not different for readings every 1 hr compared to every 4 hrs. However, because ICP was not collected continuously, transient ICP elevations may have been missed. This should not imply that therapeutic response to high ICP events only occurred every 4 hrs because all centers recorded ICP continuously with more frequent internal monitoring than required by the study protocol.
CONCLUSIONS
In summary, EVD placement with CSF drainage controlled ICP >90% of the time and thrombolytic therapy appears to contribute to ICP reduction in the acute phase of IVH. Refractory intracranial hypertension is an independent risk factor for mortality. This study also supports that administration of thrombolytic agents can be performed without additional ICP management in the majority of patients, but that close ICP monitoring during EVD closure is essential to treat ICP elevations, which in most cases respond quickly to hyperventilation or mannitol without the need for EVD opening.
Our study suggests there could be further benefit in preventing episodes of ICP elevation >30 mm Hg during the acute phase of ICH with IVH. Assuming ICP management was optimized in these patients, further strategies to treat intractable ICP elevation should be investigated as to whether they may improve mortality or whether this reflects a more severe injury with permanent structural damage. A better understanding of the pathophysiology of intracranial hypertension in this disease will likely come from studies using cerebral microdialysis and brain tissue oxygen probes to elucidate the association of disturbances in cerebral metabolism with ICP elevation and also the relationship with long-term radiographic markers of cognitive function such as cerebral atrophy and ventricular size. ICP should be monitored early in all IVH patients during drainage and during administration of intraventricular drugs so that elevated ICP can be treated rapidly and EVDs can be appropriately managed.
